Corifact® (factor XIII concentrate [human]) Tretten® (coagulation factor XIII A-subunit [recombinant])

Corifact is covered for routine prophylaxis and perioperative management of congenital Factor XIII deficiency and Tretten is covered for routine prophylaxis of congenital Factor XIII A‑subunit deficiency; non‑congenital/acquired indications are excluded. Approvals are IV only and time‑limited (initial 3 months, renewals 12 months) and require documentation of diagnosis (A‑subunit specified for Tretten), patient weight and FXIII activity labs, and adherence to weight‑based dosing/targets (Corifact ~40 IU/kg every 28 days targeting 5–20% trough; Tretten 35 IU/kg monthly targeting ≥10%, with dose adjustments as needed).

"Corifact is indicated for routine prophylactic treatment of bleeding in adult and pediatric patients with congenital Factor XIII deficiency."

Sign up to see full coverage criteria, indications, and limitations.